

## **International Journal of Phytopharmacology**

Journal homepage: www.onlineijp.com



ISSN 0975 - 9328

## ANTICANCER AND ANTIMICROBIAL ACTIVITY OF 1-[(5-SUBSTITUTED-1,3,4 OXADIAZOL-2-YL) METHYL]-4-BENZYLPIPERAZINES

### Kantham Srinivas<sup>1</sup>, Shyamkumar Immadi<sup>2,\*</sup>, Sandeepkumar M<sup>2</sup>, Gowtham Dontheboina<sup>2</sup>, Anusha Domakonda<sup>3</sup>, Avinash Modumpally<sup>4</sup>.

 <sup>1</sup>Department of Pharmaceutical Chemistry, Sri Rajya Laxmi (SRL) Institute of Pharmaceutical Sciences, Kummarigudem Road, Madikonda, Kazipet, Warangal, Andhra Pradesh, India- 506003.
<sup>2</sup>Pragathi Pharmacy College, Pembarty, Jangaon, Warangal, Andhra Pradesh, 506167.
<sup>3</sup>Balaji Institute of Pharmaceutical Sciences. Narsampet, Warangal, Andhra Pradesh, 506132.
<sup>4</sup>St. peters college of pharmacy, Madikonda, Warangal, Andhra Pradesh, 506142.

### ABSTRACT

The synthesis of 1-[(5-sustituted-1,3,4-oxadiazol-2-yl) methyl]-4-benzylpiperazines **VIa-j** was carried out by refluxing the 1-benzylpiperazine **II** with ethylchloroacetate **III** in dry acetone in the presence of potassium carbonate and subsequent hydrazinolysis with hydrazine hydrate. Finally 2-(4-benzylpiperazin-1-yl)aceto- hydrazide **V** was treated with appropriate carboxylic acids in the presence of phosphorous oxy chloride to produce title compounds. All the title compounds (VIa-j) were screened for anticancer activity using HBL-100 cell lines by MTT method and antibacterial activity against *B. subtiliis, S.aureus, E.coli* and *P.vulgaris*. The structures of newly synthesized compounds were established on the basis of elemental analysis, IR, <sup>1</sup>H NMR and mass spectral data.

Keywords:- Anticancer, antimicrobial, antifungal, piperazine and oxadiazole.

#### INTRODUCTION

Piperazine derivatives have been extensively investigated by the medicinal chemists due to their close association with various types of biological activities. Benzylpiperazine and Oxadiazole analogs are associated with a variety of pharmacological activities including anthelmintic, antibacterial, anti-HIV(El-Emam *et al.*, 2004), antifungal, genotoxic (Maslat *et al.*, 2002), antitubercular (Kucukguzel *et al.*, 2002), virucidal (Chauhan *et al.*, 2003), antimalarial (Kagthara *et al.*, 1999), insecticidal (Mohan *et al.*, 2004), anticonvulsant (Khan *et al.*, 2001), sedative, hypnotic (Maillard *et al.*, 1962), anticancer (Jessen *et al.*, 2005) and lipid peroxidation inhibitor (Farghaly *et al.*, 2000).

\*Corresponding Address

#### Shyamkumar Immadi

E Mail: shyam.immadi@gmail.com

The oxadiazole chemistry has been developed extensively and is still developing. Presently there are a number of drugs used clinically, which comprise oxadiazole moiety in association with various heterocyclic rings. In view of these, a project was undertaken to synthesize a new series of 1,3,4oxadiazoles containing the 4-propyl- piperazine moiety by microwave irradiation and to evaluate the new compounds for their pharmacological activity. The title compounds were screened for anticancer activity by MTT method (Krief et al., 1989) and antimicrobial activity by cup plate method (Seely et al., 1975). Synthesis of title compounds was shown in Scheme 1: Synthesis of 1-[(5methyl]-4sustituted-1,3,4-oxadiazol-2-yl) benzylpiperazines.

#### MATERIALS AND METHODS

Melting points were determined in open capillary tubes, using Toshniwal melting point apparatus and are uncorrected. IR spectra were recorded on Perkin – Elmer spectrum BX-I series, FT IR spectrophotometer using KBr discs. PMR spectra were recorded on Brucker spectrospin 400 MHz spectrophotometer using TMS as an internal standard. Purity was checked by TLC using TLC aluminum sheets silica gel 60, supplied by E.Merk, Mumbai, India.

#### **Anticancer Activity**

1-[(5-sustituted-1,3,4-oxadiazol-2-yl) methyl]-4benzylpiperazines were subjected to in vitro MTT [3-(4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium Bromide] assay to detect cytotoxic antitumor property and in vivo test using tumor mouse model to detect noncytotoxic antitumor property were used. MTT assay was used for in vitro cytotoxicity test. Cells were harvested from experimental-phase maintenance cultures. Four hundred cells were counted by trypan blue exclusion and dispensed within triplicate 96-well culture plates in 100 µl volumes for each venom concentration. The assay at each concentration was repeated twice. The cell proliferation activity was qualified on HBL-100 (ICLC NO. HTL 00004)- breast myoepithelial tumor cell line, by using Cisplatin as a standard. The results are represented in Table1.

#### **Antimicrobial Activity**


The antimicrobial activity of all the newly synthesized compounds were determined by well plate method in nutrient agar (Hi-Media) was used for antibacterial activity. The antibacterial activity of the test compounds was assayed against *Bacillus subtilis*, *Staphylococcus aureus* (gram – positive) and *Escherichia coli* and *Proteus vulgaris* (gram – negative) by CUP-plate method.

The compounds were tested at a concentration of a 100  $\mu$ g/ml were prepared in dimethylformamide (DMF). The Petri dishes used for antibacterial screening were incubated at 37  $\pm$  1° for 24 h; the diameters of zone of inhibition (mm) surrounding each of the wells were recorded. The results were compared with Ciprofloxacin of a 100  $\mu$ g/ml concentration. The results are represented in Table1.

#### Preparation of 1-benzylpiperazine (II)

To a solution of piperazine **I** (10 g, 0.116 mol) in DMSO (30 ml), anhydrous cesium carbonate (60.0 g, 0.184 mol), sodium iodide (2.78 g, 0.0186 mol) and benzyl chloride **II** (13.32 ml, 0.116 mol) were added. The resulting mixture was stirred at 25-30  $^{0}$ C for 12 hours. The reaction mass was diluted with water (200 ml) and extracted with ethyl acetate (2 x 200 ml). The ethyl acetate layer was washed with water (2 x 100 ml), dried over anhydrous sodium sulfate (10.0 g) and concentrated under vacuum. The crude product thus obtained was purified by column chromatography (stationary phase silica gel 60-120 mesh; mobile phase 20% ethyl acetate in hexane). The compound **II** was confirmed by <sup>1</sup>H-NMR spectrum.

<sup>1</sup>H-NMR (DMSO-d  $_{6}$ , 400 MHz), δ (ppm): 2.0 (s, 1H, NH), 2.46 (m, 4H, 2CH<sub>2</sub>), 2.72 (m, 4H, 2CH<sub>2</sub>), 3.65 (m, 2H, CH<sub>2</sub>), 7.11-7.30 (m, 5H, Ar-H).



Scheme 1

## Preparation of Ethyl 2-(4-benzylpiperazin-1-yl) acetate (IV)

A mixture of 1-benzylpiperazine II (10g, 0.0567mol), ethyl chloroacetate III (6.06 g, 0.0567mol) and potassium carbonate (8g, 0.0817mol) in dry acetone (500 mL) was refluxed for 20 h. The reaction mixture was filtered hot and the solvent was distilled off from the filtrate. The crude ester thus obtained was purified by recrystalization from ethanol.

#### Preparation of 2-(4-benzylpiperazin-1yl)acetohydrazide (V)

A mixture of Ethyl 2-(4-benzylpiperazin-1-yl) acetate **IV** (10 g, 0.0382mol) and hydrazine hydrate (99%, 1.2 ml, 0.0382mol) in ethanol (100mL) was refluxed for 8 h. The solution on cooling gave a solid mass of hydrazide **4**, which was collected by filtration, and recrystallized from ethanol. The analytical data:

IR (KBr) (cm <sup>-1</sup>): 1016 (N-N), 1690 (C=O), 1611 (C=N), 3322 (-NH). <sup>1</sup> H-NMR (DMSO-d <sub>6</sub>, 400 MHz),  $\delta$  (ppm): 2.44 (s, 8H, 4CH<sub>2</sub>), 3.32 (s, 2H, CH<sub>2</sub>), 3.66 (s, 2H, CH<sub>2</sub>), 4.4 (s, 2H, NH<sub>2</sub>), 7.10-7.30 (m, 5H, Ar-H), 9.1 (s, 1H, NH)

# Preparation of 1-[(5-sustituted-1,3,4-oxadiazol-2-yl) methyl]-4 benzylpiperazines (VIa-j)

To a mixture of substituted carboxylic acid (0.02)

mol) and hydrazide V (0.02 mol), phosphorous oxychloride (5 mL) was added. The reaction mixture was refluxed for 4–6 h on an oil bath; the contents were cooled to room temperature and poured onto crushed ice.

It was then neutralized by 5% sodium bicarbonate solution. The solid that separated was collected by filtration through a Büchner funnel and dried. Further purification was done by recrystalization from a mixture of ethanol-DMF to give title compounds (Priya *et al.*, 2007). A typical compound **VIa** is described below. **2-phenyl-5-((4-benzylpiperazin-1-yl)methyl)-1,3,4-**

**oxadiazole (VIa)** IR (KBr) (cm<sup>-1</sup>): 1006(N-N), 1688 (C=O), 1611 (C=N), 1259 (C-O-C). <sup>1</sup> H-NMR (DMSO-d<sub>6</sub>, 400 MHz), δ (ppm): 2.48 (s, 8H, CH<sub>2</sub>), 3.7 (s, 4H, 2CH<sub>2</sub>), 7.0-7.90 (m, 10H, Ar-H). LC-MS (m/z): 335.18 (M+1).

Table 1. Anticancer and antibacterial activity of 1-[(5-sustituted-1,3,4-oxadiazol-2-yl) methyl]-4-benzylpiperazines (VIa-j)

| Compound   | R                             | Cytotoxic<br>activity<br>IC <sub>50</sub> (μM) | Antibacterial activity (Zone of inhibition in mm) |              |         |             |
|------------|-------------------------------|--|---|--------------|---------|-------------|
|            |                               |  | B.<br>Subtil<br>is                                | S.<br>aureus | E. coli | P. vulgaris |
| VIa        | Phenyl                        | 78   | 16  | 10           |         | 06          |
| VIb        | <i>p</i> -Anisyl              | 98   | 08  | 12           | 10      | 11          |
| VIc        | o-Tolyl                       | 38   | 20  | 18           | 16      | 15          |
| VId        | <i>p</i> -Tolyl               | 42   | 15  | 08           | 12      | 10          |
| VIe        | p-Chlorophenyl                | 34   | 10  | 10           | 11      | 09          |
| VIf        | 3-Pyridyl                     | 30   | 15  | 17           | 14      | 12          |
| VIg        | 2-Furyl                       | 66   | 17  | 18           | 15      | 14          |
| VIh        | <i>p</i> -Phenoxy methyl      | 96   | 11  | 12           | 11      |             |
| VIi        | <i>p</i> -Cresyloxy<br>methyl | 171  | 06  | 10           | 10      | 08          |
| VIj        | o-Cresyloxy<br>methyl         | 135  |   | 08           | 02      | 06          |
| Cisplatin  | -                             | 25   | NA  | NA           | NA      | NA          |
| Ampicillin | -                             | NA   | 22  | 20           | 18      | 17          |

#### **RESULTS AND DISCUSSION**

The title compounds were characterized by their physical, analytical and spectral data and the title compounds were obtained in good yields and purity.

All the test compounds at the conc. of 20  $\mu$ g/ml, 80  $\mu$ g/ml, 100  $\mu$ g/ml and 200  $\mu$ g/ml were taken to evaluate the anticancer activity against HBL-100 cell lines and the results are presented as IC<sub>50</sub> values. All the compounds showed anticancer activity in the range of 31  $\mu$ M to 171  $\mu$ M. The structure activity studies reveal that among the test compounds, the compound VIf with Pyridyl substitution at C-5 position on oxadiazole moiety showed relatively high degree of anticancer activity with IC<sub>50</sub> of 30  $\mu$ M. The compounds, VIe, VIc, VId, VIg was next in the order of anticancer activity with IC<sub>50</sub> values of 34  $\mu$ M and 38  $\mu$ M, 42  $\mu$ M respectively. The results are statistically significant and the activity of the compounds is compared with the standard Cisplatin.

The antibacterial data of 1-[(5-sustituted-1,3,4oxadiazol-2-yl) methyl]-4-benzylpiperazines (VIa-l) given in Table 1 indicates that these compounds mild antibacterial activity at the concentration of 100  $\mu$ g/disc against gram-positive organism (*B. subtilis, S. aureus*) and gram negative (*E. coli, P. vulgaris*) organisms. The compound VIc was more active among all the test compounds followed by compound VIc, VIg, VId.

#### ACKNOWLEDGMENTS

The authors are thankful to the Director and Principal, Pragathi Pharmacy College, Pembarty, Jangaon, Warangal, Andhra Pradesh and Department of Pharmaceutical Chemistry, Sri Rajya Laxmi (SRL) Institute of Pharmaceutical Sciences, Kummarigudem Road, Madikonda, Kazipet, Warangal, A.P India, for providing laboratory facilities and financial support.

#### REFERENCES

- Chauhan D, Chauhan JS, Singh J, Bajpai SK, Joshi MN. Synthesis and bioevaluation of some novel nucleosides as antiherptic agents. *Indian J Chem.*, 42B, 2003, 215-8.
- El-Emam AA, Al-Deeb OA, Al-Omar M. Synthesis, antibacterial and anti-HIV activity of certain 5-(1-adamantyl)-2substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazolin-2-thiones. *Bioorg Med Chem.*, 12, 2004, 5107-13.
- Farghaly AA, Bekhit AA, Park JY. Design and synthesis of some oxadiazolyl, thiazolidinyl and thiazolyl derivatives of 1Hpyrazole as anti-inflammatory and antimicrobial agents. *Arch Pharm.*, 333, 2000, 53-7.
- Jessen KA, English NM, Wang JY, Maliartenou SK, Archer SP, Qiu L, *et al.* The discovery and mechanism of action of novel tumour-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach. *Mol Cancer Ther.*, 4, 2005, 761-71.
- Kagthara PR, Shah NS, Doshi RK, Parekh HH. Synthesis of 2,5-disubstituted-1,3,4-oxadiazoles as biologically active heterocycles. *Indian J Chem.*, 38B, 1999, 572-6.
- Khan MS, Khan RM, Drabu S. Anticonvulsant and antibacterial activity of some new 1,3,4-oxadiazole derivatives. *Indian J Heterocycl Chem.*, 11, 2001, 119-22.
- Krief P, Saint-Ruf C, Bracke M, Boucheix C, Billard C, Billard M, et al. Acquisition of tumorigenic potential in the human myoepithelial HBL 100 cell line is associated with decreased expression of HLA class I, class II and integrin beta 3 and increased expression of C-myc. Int J Cancer, 43, 1989, 658-64.
- Kucukguzel SG, Oruc EE, Rollas S, Sahin F, Ozbek A. Synthesis, characterization and biological activity of novel 4thiazolidinones, 1,3,4-oxadiazoles and some related compounds. *Eur J Med Chem.*, 37, 2002, 197-206.
- Maillard J, Vincent M, Morin R, Bernard M. Hypnotic and sedative drug, 2-(o-hydroxyphenyl)-1,3,4-oxadiazole. French Pat M379. *Chem Abstr.*, 57, 1962, 15251.
- Mohan TP, Vishalakshi B, Bhat KS, Kendappa GN. Synthesis and insecticidal activity of some 1,3,4-oxadiazole derivatives containing phenoxy fluoro group. *Indian J Chem.*, 43B, 2004, 1798-801.
- Priya V Frank, Girish K S, Balakrishna Kalluraya. Solvent-free microwave-assisted synthesis of oxadiazoles containing imidazole moiety. J. Chem. Sci., 119, 2007, 41–46.
- Seely HW, Van Demark PJ. Microbes in action: A laboratory manual of Microbiology, Mumbai: DB Taraporewala Sons and Co; 1975. 55.